Follow-On Biologics Face Negotiation Slalom After Scaling Mount PDUFA

Creation of an approval pathway for follow-on biologics appears probable after proponents attached placeholder language to the user fee reauthorization bill in the Senate, but the generic industry and their allies still face considerable challenges to enacting legislation they find favorable